{
  "documentMetadata": {
    "title": "Corynebacterium minutissimum",
    "lastUpdated": "2025-01-31",
    "sourceFile": "Corynebacterium minutissimum.pdf"
  },
  "content": [
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Clinical Setting"
        },
        {
          "type": "list",
          "items": [
            "Corynebacterium minutissimum is an aerobic gram-positive rod that causes the clinical skin condition called erythrasma.",
            "Erythrasma presents as scaly skin plaques between the toes and/or thin brownish plaques in intertriginous areas like the upper inner thighs or axilla.",
            "As such erythrasma is often mistaken for Tinea pedis, Tinea cruris, or Tinea versicolor.",
            "Diagnosis is made by coral-red appearance of the skin when exposed to a Wood's lamp (UV wavelength 365nm)."
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Classification"
        },
        {
          "type": "list",
          "items": [
            "Aerobic gram positive rod"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Primary Regimens"
        },
        {
          "type": "list",
          "items": [
            "Topical therapy for mild localized disease"
          ]
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Clindamycin",
                "dose": "1% lotion",
                "route": "apply bid or tid",
                "frequency": "x 14 days"
              }
            ]
          }
        },
        {
          "type": "list",
          "items": [
            "Concomitant use of antibacterial soap may decrease number of recurrences"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Alternative Regimens"
        },
        {
          "type": "list",
          "items": [
            "For widespread infection, systemic therapy is indicated"
          ]
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Clarithromycin",
                "dose": "500 mg",
                "route": "po bid",
                "connector": "or"
              },
              {
                "drug": "Erythromycin",
                "dose": "250 mg",
                "route": "po bid",
                "frequency": "x 14 days"
              }
            ]
          }
        },
        {
          "type": "list",
          "items": [
            "Single dose Clarithromycin 1,000 mg po has been reported to be effective (Intern J Dermatol 52: 516, 2013; J Dermatol Treat 24: 70, 2013)"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Comments"
        },
        {
          "type": "list",
          "items": [
            "May be the presenting sign of diabetes mellitus.",
            "Skin lesions may be asymptomatic.",
            "If frequent recurrences, use of antibacterial soap or topical benzoyl peroxide washes may help.",
            "Very rare cause of systemic infection including bacteremia, endocarditis, meningitis (J Infect 56: 77, 2008)",
            "In vitro susceptibilities: low MICs of vancomycin; strains with high MICs identified for ampicillin, erythromycin, clindamycin, ciprofloxacin and others (Antimicrob Agents Chemother 39: 208, 1995).",
            "Report of frequent erythromycin resistance from Turkey (J Am Acad Dermatol 65: 1230; 2011)",
            "Successful treatment of 9 men with topical 2% mupirocin bid x 2-4 weeks (Dermatol Online J 23(5): 10, 2017)"
          ]
        }
      ]
    }
  ]
}
